You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
Baxter
Harvard Business School
McKesson

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Doxycycline hyclate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for doxycycline hyclate and what is the scope of freedom to operate?

Doxycycline hyclate is the generic ingredient in fifteen branded drugs marketed by Pliva, Mayne Pharma Intl, Warner Chilcott, Medicis, Almirall, Teva, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Alembic Pharms Ltd, Amneal Pharms, Changzhou Pharm, Chartwell Life Sci, Halsey, Heather, Hikma Intl Pharms, Interpharm, Mutual Pharm, Mylan, Par Pharm, Pvt Form, Ranbaxy, Sun Pharm Industries, Superpharm, Watson Labs, Zhejiang Yongtai, Zydus Pharms, Collagenex, Pfizer, Fresenius Kabi Usa, Rachelle, Mylan Labs Ltd, West-ward Pharms Int, Den-mat, Mayne Pharma, Actavis Elizabeth, Heritage Pharms Inc, Impax Labs Inc, Mylan Pharms Inc, Prinston Inc, Amneal Pharms Co, Apotex, Cadila, Caribe Holdings, Emcure Pharms Ltd, Epic Pharma Llc, Heritage Pharma, Lannett Co Inc, Larken Labs, Lupin Ltd, Mayne Pharma Inc, Novel Labs Inc, Oaklock Llc, Vintage Pharms, Chartwell Pharma, and Galderma Labs Lp, and is included in eighty-five NDAs. There are five patents protecting this compound and seven Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Doxycycline hyclate has two patent family members in two countries.

There are twenty-eight drug master file entries for doxycycline hyclate. Seventy-two suppliers are listed for this compound.

Drug Prices for doxycycline hyclate

See drug prices for doxycycline hyclate

Drug Sales Revenue Trends for doxycycline hyclate

See drug sales revenues for doxycycline hyclate

Recent Clinical Trials for doxycycline hyclate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of PennsylvaniaPhase 4
University of IowaPhase 2
Galderma R&DPhase 4

See all doxycycline hyclate clinical trials

Pharmacology for doxycycline hyclate
Paragraph IV (Patent) Challenges for DOXYCYCLINE HYCLATE
Tradename Dosage Ingredient NDA Submissiondate
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2017-09-28
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2017-09-28
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2015-11-05
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2015-11-05
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2015-07-01
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2015-07-01
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2014-05-19
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2014-05-19
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2008-12-19
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2008-12-19

US Patents and Regulatory Information for doxycycline hyclate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galderma Labs Lp PERIOSTAT doxycycline hyclate TABLET;ORAL 050783-001 Feb 2, 2001 DISCN Yes No   Start Trial   Start Trial   Start Trial
Mylan Labs Ltd DOXYCYCLINE doxycycline hyclate INJECTABLE;INJECTION 091406-001 Aug 21, 2012 AP RX No No   Start Trial   Start Trial   Start Trial
Teva DOXY-LEMMON doxycycline hyclate CAPSULE;ORAL 062497-001 Aug 23, 1984 DISCN No No   Start Trial   Start Trial   Start Trial
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-008 May 20, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Superpharm DOXYCYCLINE HYCLATE doxycycline hyclate CAPSULE;ORAL 062469-002 Oct 31, 1984 DISCN No No   Start Trial   Start Trial   Start Trial
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-005 Apr 11, 2013 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Chartwell Pharma LYMEPAK doxycycline hyclate TABLET;ORAL 209844-001 Jun 15, 2018 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKinsey
Express Scripts
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.